Spruce Biosciences (SPRB) Gains from Investment Securities (2025 - 2026)
Spruce Biosciences (SPRB) posted quarterly Gains from Investment Securities of $91000.0 for Q1 2026, up 157.59% year-over-year from $35326.8 in Q1 2025, and down 97.73% quarter-over-quarter from $4.0 million in Q4 2025.
Spruce Biosciences (SPRB) Gains from Investment Securities (2025 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Gains from Investment Securities for 2 consecutive years, with $91000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 157.59% year-over-year to $91000.0; the TTM figure through Mar 2026 stood at $3.7 million (up 2472.78% YoY), while the FY2025 annual figure was $3.5 million, changed N/A from the prior year.
- Gains from Investment Securities retreated to $91000.0 in Q1 2026 per SPRB's latest filing, from $4.0 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $4.0 million in Q4 2025 and bottomed at -$461000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -615,000.00 |
| Jun 30, 2026 | -615,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | 4.02 Mn |
| Dec 31, 2025 | 4.02 Mn |
| Sep 30, 2025 | 102,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | -461,000.00 |
| Jun 30, 2025 | -461,000.00 |
| Mar 31, 2025 | -158,000.00 |
| Mar 31, 2025 | -158,000.00 |